Cynata Therapeutics Ltd
ASX:CYP

Watchlist Manager
Cynata Therapeutics Ltd Logo
Cynata Therapeutics Ltd
ASX:CYP
Watchlist
Price: 0.315 AUD Market Closed
Market Cap: AU$74.8m

Operating Margin

-4 120.9%
Current
Declining
by 340.6%
vs 3-y average of -3 780.3%

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
-4 120.9%
=
Operating Income
AU$-9.4m
/
Revenue
AU$227.7k

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
-4 120.9%
=
Operating Income
AU$-9.4m
/
Revenue
AU$227.7k

Peer Comparison

Country Company Market Cap Operating
Margin
AU
Cynata Therapeutics Ltd
ASX:CYP
71.2m AUD
Loading...
FR
Pharnext SCA
OTC:PNEXF
6T USD
Loading...
US
Abbvie Inc
NYSE:ABBV
385B USD
Loading...
US
Amgen Inc
NASDAQ:AMGN
184.4B USD
Loading...
US
Gilead Sciences Inc
NASDAQ:GILD
169B USD
Loading...
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
118.3B USD
Loading...
US
Epizyme Inc
F:EPE
94.1B EUR
Loading...
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
79.1B USD
Loading...
AU
CSL Ltd
ASX:CSL
87B AUD
Loading...
NL
argenx SE
XBRU:ARGX
43.2B EUR
Loading...
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
47.8B USD
Loading...

Market Distribution

Lower than 86% of companies in Australia
Percentile
14th
Based on 3 951 companies
14th percentile
-4 120.9%
Low
-14 949 200% — -526.4%
Typical Range
-526.4% — 6.1%
High
6.1% — 145 596.9%
Distribution Statistics
Australia
Min -14 949 200%
30th Percentile -526.4%
Median -25.2%
70th Percentile 6.1%
Max 145 596.9%

Cynata Therapeutics Ltd
Glance View

Market Cap
74.8m AUD
Industry
Biotechnology

Cynata Therapeutics Ltd. engages in the development and commercialization of therapeutic products. The firm is engaged in the development and commercialization of a mesenchymal stem cell (MSC) technology for human therapeutic use, which the Company has branded as Cymerus. The Cymerus technology facilitates the manufacture of MSCs from a single donor and a single donation, which enables the development of therapeutic stem cell products. The firm's Cymerus platform stem cell technology is based upon stem cells known as mesenchymoangioblasts (MCAs). Its technology utilizes induced pluripotent stem cells (iPSCs) originating from an adult donor as the starting material for generating MCAs and in turn for manufacturing the MSC therapeutic product. The Company’s lead product candidate, CYP-001, which has met all clinical endpoints and demonstrated safety and efficacy data for the treatment of steroid-resistant acute graft-versus-host disease (GvHD) in a Phase I trial.

CYP Intrinsic Value
0.088 AUD
Overvaluation 72%
Intrinsic Value
Price
What is Operating Margin?
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
How is Operating Margin calculated?

Operating Margin is calculated by dividing the Operating Income by the Revenue.

Operating Margin
-4 120.9%
=
Operating Income
AU$-9.4m
/
Revenue
AU$227.7k
What is Cynata Therapeutics Ltd's current Operating Margin?

The current Operating Margin for Cynata Therapeutics Ltd is -4 120.9%, which is below its 3-year median of -3 780.3%.

How has Operating Margin changed over time?

Over the last 3 years, Cynata Therapeutics Ltd’s Operating Margin has decreased from -85.8% to -4 120.9%. During this period, it reached a low of -5 633.6% on Dec 31, 2022 and a high of -85.8% on May 30, 2022.

Back to Top